Colorectal cancer develops in the colon or rectum. When cancer cells break away and spread to distant organs like the liver or lungs, the disease becomes metastatic colorectal cancer (mCRC). At this advanced stage, surgery alone cannot cure patients. The main treatment goals are shrinking tumors, easing symptoms, delaying disease worsening and prolonging quality of life.
The global standard first-line treatment for mCRC centers on 5-fluorouracil (5-FU), a chemotherapy drug that stops cancer cells from replicating DNA. 5-FU alone has weak anti-tumor effects, so doctors combine it with leucovorin, a folate vitamin derivative that supercharges 5-FU’s cancer-killing power.
Clinicians pair this core combination with two common chemo backbones: oxaliplatin (FOLFOX regimen) or irinotecan (FOLFIRI regimen). They also add targeted antibody drugs—bevacizumab, cetuximab or panitumumab—to block cancer growth signals. While this routine works for many patients, it has a clear flaw: leucovorin cannot act immediately inside the body. It requires chemical transformation by human enzymes to turn into its active form.
People carry different genetic variations that affect how efficiently their bodies process leucovorin. Some patients convert the drug poorly, resulting in low active folate levels inside tumors and weaker treatment effects. This gap inspired the development of arfolitixorin, a novel experimental folate therapy designed to skip this activation step entirely.
How Arfolitixorin Differs From Standard Leucovorin
Folates are essential B vitamins that all rapidly dividing cells (including cancer cells) rely on to copy DNA. 5-FU disrupts this process to kill tumor cells, and active folates amplify this blocking effect.
Leucovorin needs metabolic conversion to become functional. Arfolitixorin is manufactured as fully activated folate, ready to work the moment it enters the bloodstream. It bypasses enzyme-dependent transformation, delivering consistent high levels of active medicine to tumors regardless of a patient’s unique genetics. Scientists believe this design delivers stronger, longer-lasting anti-cancer effects alongside 5-FU for more patients.
Around 420 colorectal cancer patients have received arfolitixorin in earlier trials. The drug showed acceptable safety profiles, yet one large completed study found it only matched leucovorin’s tumor-shrinking performance, without extra benefits. Researchers later realized the doses tested back then failed to deliver enough active drug to tumor tissue.
This new clinical trial aims to solve this problem by testing higher arfolitixorin doses and optimized infusion timings. Crucially, arfolitixorin has not yet received official medical approval for mCRC treatment. This study’s job is to gather solid human data to prove its safety and potential advantages over standard care.
Overview of Trial
Sponsored by Swedish biotech company Isofol Medical AB, this Phase 1b/2 trial plans to recruit up to 90 adult mCRC patients across three German cancer centers. Charité University Medicine Berlin is already enrolling participants, while Essen and Munich university clinics will open recruitment soon. The study started in April 2025, with estimated full completion by the end of 2029. An independent safety committee monitors all patient risks throughout the research.
The trial has two separate stages with distinct purposes:
Phase 1b: Find the Safest Effective Dose
This first segment uses dose escalation to locate the maximum tolerated dose (MTD) — the highest arfolitixorin dose patients can tolerate without severe, unmanageable side effects. Up to five different dose strengths are tested with the ARFOX regimen (arfolitixorin + 5-FU + oxaliplatin + bevacizumab).
A specialized statistical method guides dose adjustments. After each small group finishes treatment, a Safety Review Committee reviews side effects, lab results and drug blood concentrations. They decide whether to raise, keep or lower the dose for the next patient group, and tweak infusion duration if high blood drug levels create safety risks. This stage also tracks how the human body absorbs and clears arfolitixorin, plus early signs of tumor shrinkage.
Phase 2: Randomized Comparison Against Standard Therapy
Once Phase 1b identifies the MTD and ideal infusion length, patients enter a randomized comparative phase. A computer randomly assigns every participant to one of three groups, removing biased patient selection:
- High-dose arfolitixorin group: The MTD identified in Phase 1b
- Low-dose arfolitixorin group: A milder dose below the MTD
- Control group (standard care): Traditional leucovorin-based chemo
Both experimental groups use arfolitixorin paired with either oxaliplatin (ARFOX) or irinotecan (ARFIRI), plus one of the three approved targeted antibodies. The control group receives identical chemo and antibody combinations, replacing arfolitixorin with leucovorin. This setup lets researchers directly compare the new drug against routine hospital treatments.
Treatment Routine & Patient Monitoring
All participants receive intravenous infusions every two weeks. The fixed treatment sequence follows the same order: targeted antibody first, then oxaliplatin or irinotecan, followed by arfolitixorin or leucovorin, and finally 5-FU injections and drips. Patients repeat cycles indefinitely as long as their cancer does not progress and side effects remain bearable.
Medical teams closely track patient health and tumor response throughout the trial:
- CT/MRI scans before treatment to record baseline tumor size
- Repeat scans at week 6, week 12, then every 12 weeks during active treatment
- Regular blood and urine tests, physical examinations, and full documentation of all side effects
After stopping study treatment, patients attend a final end-of-treatment visit within 30 days. Long-term follow-up continues every 90 days via phone calls or clinic visits for up to 24 months, tracking survival status, later cancer treatments and lingering severe side effects until symptoms stabilize or resolve.
Who Can Join the Trial?
Strict entry rules protect patient safety and ensure reliable research data.
Key Requirements to Enroll
- Aged 18 or older, able to sign consent and follow all trial rules
- Biopsy-confirmed metastatic colorectal cancer with measurable tumors on scans
- Good overall health: ECOG score 0–1 (able to complete daily tasks), life expectancy over 12 weeks
- Healthy blood cell counts and properly functioning liver/kidneys
- Tumor genetics matching eligible regimens (RAS-mutant or wild-type RAS/BRAF left-sided tumors)
- Willingness to use strict contraception for years after treatment ends Automatic Disqualifications
- Prior chemotherapy or targeted antibody treatment for metastatic colorectal cancer
- Previous use of arfolitixorin
- BRAF-mutant or mismatch repair deficient (dMMR/MSI-H) tumors
- DPD enzyme deficiency (a genetic disorder causing dangerous 5-FU toxicity)
- Brain metastases, severe heart disease, uncontrolled high blood pressure, advanced nerve damage or active IV-treated infections
- Pregnancy, breastfeeding or recent major surgery within 8 weeks What Researchers Are Measuring
Scientists track clear, measurable outcomes (endpoints) to judge arfolitixorin’s value.
Primary Key Outcomes
- Phase 1b: Assess safety and side effects; confirm the maximum tolerated dose of arfolitixorin
- Phase 2: Compare safety across all three treatment arms
- Phase 2 anti-tumor activity: Objective Response Rate (ORR, percentage of patients with fully or partially shrunk tumors) and Duration of Response (how long tumor shrinkage lasts) Secondary Supporting Outcomes
Researchers also collect extra data to fully evaluate the therapy, including time until cancer worsens (progression-free survival), total overall survival, speed of tumor shrinkage, disease control rate, maximum tumor reduction depth, drug blood concentration data, and how many patients become eligible for curative metastasis surgery after treatment. Why This Trial Matters for mCRC Patients
For years, leucovorin has been the unchanging backbone of mCRC first-line therapy, yet its inconsistent performance leaves many patients with subpar tumor control. Arfolitixorin’s pre-activated design could deliver steady, reliable folate activity for every patient, regardless of individual metabolism differences.
If the trial produces positive results, patients may gain two major benefits: deeper, longer-lasting tumor shrinkage, and effective chemo options for those who previously responded poorly to leucovorin. The study also answers practical clinical questions, such as optimal infusion length and safe dose limits that will guide hospital use if the drug wins regulatory approval.
It is important to keep realistic expectations. The trial is still recruiting, with final results unavailable until late 2029. There is no guarantee arfolitixorin will outperform standard care, and all participants receive close medical supervision to prioritize safety. The control arm ensures every volunteer has access to proven conventional cancer treatment.
Closing Thoughts
Arfolitixorin represents the next evolution of folate therapy for colorectal cancer, designed to fix leucovorin’s core metabolic limitation. This Phase 1b/2 trial is a critical research milestone to test higher doses and compare the new drug head-to-head against routine care.
As enrollment expands across Germany’s top cancer hospitals, researchers will build data that could reshape global mCRC treatment guidelines. Every patient who volunteers contributes vital knowledge to advance more effective, personalized treatments for millions living with metastatic colorectal cancer worldwide.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoRelated Clinical Trials
Chemoradiotherapy Sequenced Radical Surgery for Colorectal Cancer With PALNM
In left-sided colon and rectal cancer, the occurrence of synchronous para-aortic lymph node metastasis is rare, with the incidence of being approximate 1-2%. Currently, there has been no standard treatment strategy for this situation. The present trial is designed to evaluate the safety and efficacy of para-aortic lymph node dissection for left-sided colon and rectal cancer with synchronous para-aortic lymph node metastasis
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoTrial of Gum Chewing to Enhance the Restoration of Intestinal Motility in Colorectal Cancer Surgery
Surgery is one of the most frequent treatments of colorectal cancer. However, delayed restoration of intestinal motility is a common phenomenon in patients who undergo colorectal surgery, and may reduce comfort, prevent the early hospital discharge of patients and increase healthcare costs. Gum chewing is a kind of safe and easily accessible sham feeding to stimulate intestinal motility. In addition, prediction models were used to estimate the risk of delayed restoration of intestinal motility after colorectal surgery. Thus, this study is an External Controlled trial that will determine whether stratified application of gum chewing by risk prediction model will enhance restoration of intestinal motility and reduce healthcare costs in paitents undergoing open or laparoscopic colorectal surgery.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoStudy of Fuquinitinib Combined With Capecitabine First-line Maintenance in the Treatment of Metastatic Colorectal Cancer
This is a single-arm, single-center, prospective phase I/II study that received standard first-line chemotherapy (FOLFOX,FOLFIRI,XELOX, FOLFOXIRI± targeted therapy). If the first-line chemotherapy regimen is a 2-week regimen, patients need to undergo ≥8 cycles of standard chemotherapy. If the first-line chemotherapy regimen is a 3-week regimen, maintenance therapy is required for patients with unresectable advanced metastatic colorectal cancer who have reached CR,PR,SD (RECIST 1.1) after standard chemotherapy after ≥4 cycles. The eligible patients were screened for maintenance treatment. Maintenance therapy research is divided into the following two phases: Phase IIB fuquinitinib combined capecitabine dose exploration trial (n=6-9) : Phase II: Dose extension trial (n=47) : 47 patients were continued to be enrolled in the dose extension phase trial according to the recommended dose of fuquinitinib combined with capecitabine established in phase iB, and were treated until toxicity became intolerable or disease progression.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoSmart Measurement of Circulating Tumor DNA
The goal of this study is to develop a blood-test which can detect colorectal cancer in early stages. Participants will be asked to take an extra blood test, which will be analyzed further in the lab.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoA Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are looking for ways to stop the actions of abnormal proteins made from the mutated KRAS gene. ASP5834 is being studied in people with solid tumors who have certain KRAS gene mutations. Some people with solid tumors of the colon or rectum (colorectal cancer), will be given ASP5834 with panitumumab. Panitumumab is a treatment for colorectal cancer. In this study, the researchers will learn how ASP5834 is processed by and acts upon the body. This information will help find a suitable dose of ASP5834 and check for any potential medical problems from the treatment. The main aims of this study are to check the safety of ASP5834 given by itself or given with panitumumab, and how well it is tolerated; and to find a suitable dose of ASP5834 given by itself or given with panitumumab. People in this study will be adults with locally advanced, unresectable, or metastatic solid tumors with certain KRAS gene mutations. Locally advanced means the cancer has spread to nearby tissue. Unresectable means the cancer cannot be removed by surgery. Metastatic means the cancer has spread to other parts of the body. They either haven’t responded to standard treatment or couldn’t be given standard treatment. The key reasons people cannot take part are if they have specific uncontrollable cancers such as symptomatic or untreated cancers in nervous system, have specific heart conditions, swelling and irritation of lung tissues (pneumonitis or interstitial lung disease, also called ILD), infections, or have recently had a stroke or a bleed on the brain. In this study, ASP5834 is being given to humans for the first time. This is an open-label study. This means that people in this study and clinic staff will know that they will receive ASP5834 by itself or ASP5834 with panitumumab. This study will be in 2 parts: Part 1 is called Dose Escalation. Different small groups of people will receive lower to higher doses of either: ASP5834 by itself or ASP5834 with panitumumab. Only people who have colorectal cancer will receive ASP5834 with panitumumab. People with any type of solid tumor will receive ASP5834 by itself. For each dose, all medical problems will be recorded. A medical expert panel will check the results and decide if the next group can receive a higher dose of ASP5834. The panel will do this until the planned maximum number of people are treated or until suitable doses have been selected for Part 2. Part 2 is called Dose Expansion. Other different small groups of people will receive ASP5834 or ASP5834 with panitumumab. They will receive the most suitable doses worked out from Part 1. In both parts of the study, the study treatments ASP5834 and panitumumab will be given through a vein. This is called an infusion. Each study treatment cycle is either 21 days or 28 days long. People will continue study treatment until: they have medical problems from the study treatment they can’t tolerate; their cancer gets worse; they start other cancer treatment; or they ask to stop study treatment. People will visit the clinic on certain days during their study treatment, with extra visits during the first 2 cycles of study treatment. The study doctors will check for any medical problems from ASP5834. Also, people in the study will have a health check. On some visits they will also have scans to check for any changes in their cancer. Tumor samples will be taken at certain visits during study treatment with the option of a tumor sample being taken if people’s cancer gets worse or the cancer comes back. People will visit the clinic shortly after stopping treatment for a health check. After this, people will have health checks every couple of months to check the condition of their cancer. The number of visits and checks done will depend on the health of each person and whether they completed their study treatment or not. It is expected that people will be in this study for about 1 year.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoThe Effect of Inulin Supplementation on Colorectal Surgery Outcomes
Colorectal cancer (CRC) is the third most diagnosed cancer in Canada. The most common surgical procedure in patients with CRC is an intestinal resection followed by a reconnection to rejoin the ends of the remaining bowel. Among the postoperative complications, leaking of this intestinal connection is notably feared, affecting up to 20% of patients. These leaks are characterized by impaired intestinal healing and are associated with severe infections and even death. Various studies have shown that gut microbiota, the bacteria that live in the digestive tract, plays an essential role in intestinal healing following surgery. These results support the possibility of enhancing intestinal healing through supplements that act as an energy source for gut bacteria. Indeed, animal studies have shown that inulin supplementation, a fiber commonly found in plants, improves intestinal healing following bowel surgery. However, no studies in humans have evaluated its effects on CRC surgery patients. This study aims to determine feasibility of a randomized controlled trial that assesses the effects of inulin supplementation before elective colorectal surgery.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoMinimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients
This clinical trial compares minimal residual disease (MRD) testing with the Haystack blood test (assay) to the Signatera® assay for the early detection of the cancer returning (cancer recurrence) in patients with stage II-IV colorectal cancer (CRC) that can be removed by surgery (resectable). MRD testing looks for evidence of remaining tumor following treatment that is only apparent using highly sensitive techniques. There are few effective tools available outside of imaging to identify CRC patients with MRD who may be at the highest risk for cancer recurrence after surgery. Early detection of CRC recurrence after surgery is important, as it may increase the chance of curative (ability to cure) outcomes for patients with cancer recurrence. Currently, the Signatera assay is used to monitor whether CRC recurs after surgery, however it is not a very sensitive test. Early work with the Haystack assay suggests it may be more sensitive than the Signatera assay, which may be more effective for the early detection of cancer recurrence in patients with resectable stage II-IV CRC.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoLocally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoAn Exploratory Clinical Study Evaluating the Efficacy and Safety of Tunlametinib Combined With Fruquintinib in the Third-line Treatment of Advanced Colorectal Cancer Patients With RAS Mutations.
This study is a prospective, open-label, single-arm clinical study aimed at evaluating the efficacy and safety of Tunlametinib combined with Fruquintinib in the third-line treatment of advanced colorectal cancer patients with RAS mutations.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoMegestrol Acetate in Improving Neoadjuvant Chemotherapy-Related Weight Loss in Locally Advanced CRC
Cancer-associated anorexia, a debilitating condition characterized by progressive appetite loss in oncology patients, contributes to pancytopenia, sarcopenia, and adipose tissue depletion. Megestrol acetate (MA) improves appetite and promotes weight gain through multiple mechanisms, playing a crucial role in the nutritional management of cancer patients. Total mesorectal excision (TME) following neoadjuvant chemotherapy has become the standard treatment strategy for patients with locally advanced colorectal cancer (LACRC). Despite its oncological benefits, neoadjuvant chemotherapy frequently induces grade ≥2 gastrointestinal toxicities (including nausea, emesis, and diarrhea) that exacerbate malnutrition through appetite suppression and negative energy balance. Previous studies have demonstrated that combining MA with first-line maintenance chemotherapy in patients with metastatic colorectal cancer significantly improves appetite, increases body weight, enhances quality of life, and improves prognosis. However, the safety and efficacy of MA during the neoadjuvant treatment phase of LACRC remain unclear. This multicenter, randomized controlled clinical trial aims to evaluate the effects of MA on chemotherapy–related weight loss, anorexia, nutritional status, and chemotherapy tolerance in patients with LACRC undergoing neoadjuvant chemotherapy. Additionally, this study will assess the safety profile of MA in this clinical setting.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoArtificial Intelligence in Colonoscopy
Colorectal cancer is the second most common malignancy in the countries of the European Union. Colonoscopy is the primary method for detecting and preventing the development of colorectal cancer is endoscopic examination. This study aims to evaluate the impact of artificial intelligence on the detection rate of polyps and early stages of colorectal cancer.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoReducing Neoplasia Recurrence After Non-thermal Endoscopic Resection of Large Colorectal Polyps
The goal of this clinical trial is to clarify the role of adjuvant thermal ablation for non-thermal endoscopic mucosal resection (EMR) of large (≥20mm) flat colorectal polyps (so-called laterally spreading lesions \[LSLs\]). The hypothesis is that adding adjuvant thermal ablation to non-thermal EMR (vs no ablation) will result in lower lesion recurrence rates at 6-month follow-up, and non-inferior adverse events (AE) rates 14 days post EMR. For participants with planned EMR, endoscopists will perform non-thermal EMRs as per standard of care and: * adjuvant thermal ablation will either not be performed (control group), or will be applied to the base and outside margins of the resection site (experimental group); * then, all patients will be contacted 14-44 days after EMR, to verbally ascertain the occurrence of AEs; * then, all patients will undergo a first follow-up colonoscopy at 6 months after initial conoloscopy to assess lesion recurrence; * finally, all patients will undergo a second and final colonoscopy 18 months after EMR.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoY-90, Capecitabine, and Atezolizumab for Oligometastatic CRC
BrUOG-430 is a prospective, single-arm, phase 2 trial evaluating yttrium-90 radioembolization in combination with capecitabine and atezolizumab for the treatment of unresectable colorectal cancer liver metastases in individuals who have been treated with two or more lines of systemic therapy.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoBotensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma
This study is being done to answer the main question of: Do patients with colorectal cancer that cannot be removed by surgery, that is treated with two new immunotherapy drugs, botensilimab and balstilimab, live longer? Other important questions include: Is their quality of life better? Do their tumours slow in growth or possibly shrink in size? Are there markers in their tumour or blood that can predict whether they achieve any of these benefits? In addition, the study is done to confirm the safety of these immunotherapy drugs and to determine how long it takes for the body to metabolize them.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoContribution of Preserving the Superior Left Colic Artery to the Vascularization of the Descending Colon Prior to Colorectal Anastomosis During Left-Sided or Rectal Resections for Colorectal or Ovarian Cancer. (Revascularisation Colique)
Colorectal cancers and ovarian cancers are respectively the 2nd and 5th cause of cancer mortality in France. Surgical resection is a crucial step in the therapeutic management of colorectal cancers. For advanced ovarian cancers, the objective of cytoreductive surgery is to obtain complete macroscopic resection with no visible residual disease. One or more digestive resections are often required to achieve this goal of complete surgery (usually a modified posterior pelvic exenteration with colorectal resection). A ligation of the inferior mesenteric artery at its origin is classically performed in left colectomies and rectal resection for colorectal cancers. This allows the resection of the colorectal segment with a complete mesocolic lymphadenectomy until the origin of the inferior mesenteric artery and a good mobilization of the descending colon to allow its anastomosis to the underlying rectal stump. This ligation of the inferior mesenteric artery at its origin is also frequently performed in cases of modified posterior pelvic exenteration for ovarian cancer. Recently, several studies suggest that arterial ligation of the inferior mesenteric artery could be performed below the emergence of the left colic artery. Its preservation requiring a meticulous vascular dissection would allow a better vascularization of the descending colon and of the colorectal anastomosis without affecting the carcinologic quality of the resection and the number of resected lymph-nodes. Indeed, the most feared complication during colorectal anastomosis is the anastomotic leakage whose rates are on average 15% in rectal cancer with low anastomosis and 6% in ovarian cancers. Verifying the adequate vascularization of the descending colon before performing the colorectal anastomosis is a crucial step in reducing the risk of postoperative fistula. However, quantifying this vascularization is challenging, and several techniques can be used to assess it. The gold standard technique involves measuring arterial pressure using a catheter inserted into the marginal artery of the descending colon. Other non-invasive techniques also use Doppler studies to calculate pressure in the marginal artery or assess oxygen saturation using a sterile sensor. Studies have shown that the use of indocyanine green in colorectal surgery, particularly to evaluate perfusion before the creation of an anastomosis, significantly reduces the rate of anastomotic leakage. Indocyanine green is a fluorescent dye that, after intravenous injection, binds to plasma proteins and allows tissue perfusion to be visualized using a fluorescence system. The objective of this project is to show that the preservation of the left colic artery is possible and allows a better vascularization of the descending colon before colorectal anastomosis.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoHolistic Acupuncture for Patients With Chemotherapy Induced Nausea
The study explores whether acupuncture as a supplement to conventional antiemetic medicine is superior in reducing the level of chemotherapy induced nausea compared to conventional anitemetic medicine alone. A total of 90 patients experiencing chemotherapy induced nausea will be allocated 1:1 to either acupuncture and antiemetic medicine or antiemetic medicine alone. The level of nausea and other cancer related symptoms will be assessed at baseline and 8 and 22 days after enrollment
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoIntrathecal Morphine Versus Epidural Analgesia for Open Colon Surgery
Effective pain management after abdominal surgery is essential for recovery. This study compares two pain relief methods-intrathecal morphine (a single spinal injection) and continuous epidural analgesia-for patients undergoing open colorectal cancer surgery. The investigators expect intrathecal morphine to provide equal pain relief at rest 24 hours after surgery, while epidural analgesia may be more effective during movement. By 48 to 72 hours, both methods should offer similar pain control. The epidural group may require fewer additional pain medications but could experience more side effects, including a higher risk of low blood pressure and technical difficulties. Additionally, these patients may have a slightly longer hospital stay. In contrast, the intrathecal morphine group may have fewer overall side effects. Despite these differences, patient satisfaction, sleep quality, and recovery are expected to be similar in both groups. By evaluating these methods, this study aims to determine the most effective and safe approach to post-surgical pain management, improving comfort and recovery outcomes for patients.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoA Comparison of the Resection Rate for Hot and Cold Snare Polypectomy of Colorectal Polyps (10-15 Mm)
Colorectal cancer (CRC) has become the third most common malignant tumor and is the second leading cause of cancer related deaths worldwide. Adenomatous polyps of the colon are possible precursor lesions for CRC. Screening for CRC has been shown effective in preventing CRC and related deaths, especially colonoscopy and resection of adenomatous polyps. Currently, for intermediate sized polyps 5 – 19 mm hot snare polypectomy (HSP) with the use of electrocautery is conventionally used, causing relevant adverse events including haemorrhage and postpolypectomy coagulation syndrome, but is safe regarding complete resection of the polyp due to burning effect on residual tissue. On the other hand, cold snare polypectomy (CSP) has grown popularity. Absence of electrocautery makes it technically easier and most important reduces adverse events. CSP is recommended as the preferred technique for polyps \<5 mm by the European Society of Gastrointestinal Endoscopy (ESGE) guidelines. In literature, there is one multicenter trial from Japan recommending CSP for polyps 4-9 mm (average polyp size 5,4 mm) and only a few case studies for polyps 10-15 mm with inconsistent results, especially regarding the complete resection and pathological evaluation of the specimen. In this randomized controlled trial, the investigators want to compare the complete resection rates of small and intermediate sized colorectal polyps 10-15 mm with CSP and HSP.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoMepilex Lite Dressings for the Treatment of Acute Radiation Dermatitis of Anal Canal Skin
Background: According to GLOBOCAN 2022 statistics, colorectal cancer has become the third most common cancer disease worldwide, and also the second leading cause of death. The incidence rate of rectal cancer is particularly prominent. Radiotherapy is one of the important methods for comprehensive treatment of rectal cancer, but the radiation damage caused by radiotherapy cannot be ignored. During radiotherapy for rectal cancer, the skin of the anal canal will be damaged by radiation, resulting in acute radiation dermatitis, which is characterized by redness, pain, and ulcers. The main symptom of patients is anal pain. As the radiation dose accumulates, the skin damage to the anal canal becomes increasingly severe, and the patient’s anal pain becomes more severe, which seriously affects the patient’s quality of life. Mepilex Lite Dressings can absorb the exudate, keep it moist, promote the healing of radioactive dermatitis, and relieve pain. However, when inserting into the anal canal, the patient reported significant pain that was difficult to tolerate. Therefore, indomethacin suppositories were administered rectally before inserting the dressing, which has been proven to have a reliable analgesic effect by research. In summary, the main objective of this study is to determine the effectiveness of Mepilex Lite Dressings combined with indomethacin suppositories in the treatment of acute radiation dermatitis of anal canal skin in patients with rectal cancer undergoing radiotherapy. Method: The research plan will be a prospective randomized controlled trial. Participants were randomly divided into an experimental group (n=137) and a control group (n=137) using a simple randomization method. The control group received indomethacin suppositories and routine nursing measures, while the experimental group received the same treatment as the control group and received insertion of Meipile Lite Dressing into the anal canal. The primary outcome measure was the effective rate of treatment for acute radiation dermatitis of the anal canal skin on the 14th day after intervention, and the secondary outcome measure was the effective rate of treatment for acute radiation dermatitis of the anal canal skin on the 7th and 21st days after intervention. At the same time, a questionnaire survey was conducted using the Digital Pain Assessment Scale, Anxiety and Depression Scale, Pittsburgh Sleep Quality Index, and Skin Disease Patient Quality of Life Scale at baseline and on the 7th, 14th, and 21st days after intervention.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoVirtual vs Physical Art Therapy for Anxiety, Psychological Well-being, and Sleep Quality in Colorectal Cancer Patients
This randomized controlled trial aims to evaluate the effects of virtual reality-based art therapy and physical art therapy on anxiety, psychological well-being, and sleep quality in patients with colorectal cancer receiving outpatient chemotherapy. A total of 78 patients will be randomly assigned to three groups: a virtual reality art therapy group, a physical art therapy group, and a control group. Participants in the intervention groups will receive art therapy sessions every two weeks for eight weeks (four sessions in total). Anxiety, psychological well-being, and sleep quality will be assessed using validated scales before the intervention and after the fourth session. The findings are expected to contribute to the development of non-pharmacological supportive care interventions for oncology patients.
PDF$29 only! Buy Clinical Trial Full Report With Contact Info